Aratana Therapeutics (PETX) reported earnings on Thur 1 Nov 2018 (a/h)

** charts before earnings **

 

** charts after earnings **

LEAWOOD, Kan. (AP) _ Aratana Therapeutics Inc. (PETX) on Thursday reported third-quarter net income of $8.8 million, after reporting a loss in the same period a year earlier.

On a per-share basis, the Leawood, Kansas-based company said it had profit of 19 cents.

The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 13 cents per share.

The developer of pet medications posted revenue of $21.6 million in the period, which also beat Street forecasts. Three analysts surveyed by Zacks expected $5.7 million.

Aratana shares have risen 20 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $6.33, a rise of 12 percent in the last 12 months.

=Aratana Therapeutics (PETX) cancels stock offering after shares plunge

Aratana Therapeutics (PETX) canceled plans for a stock offering Tuesday afternoon, one day after it announced the equity issuance and saw its share price plunge in response. The pet-medicine company said in a news release late Tuesday that it was canceling the offering because "current market conditions are not conducive for an offering." After announcing plans to sell at least $35 million in fresh shares Monday evening, Aratana stock plunged 19% in Tuesday's regular trading session to close at $5.86. The stock rebounded after the offering was canceled Tuesday, gaining more than 10% to hit $6.50 in after-hours trading.

Aratana Therapeutics (PETX) reported earnings Thur 2 Nov 2017 (a/h)

** charts after earnings **

 

Aratana Therapeutics beats by $0.04, misses on revs 

• Reports Q3 (Sep) loss of $0.21 per share, $0.04 better than the Capital IQ Consensus of ($0.25); revenues rose 1440.0% year/year to $6.16 mln vs the $6.47 mln Capital IQ Consensus.
  • Revenues primarily included ~$4.0 mln of product sales and $2.2 mln in GALLIPRANT licensing and collaboration revenue. The product sales include $3.2 mln related to GALLIPRANT product sales as finished goods under its supply arrangement with Elanco and $717 thousand in NOCITA net sales. For the nine-month period ended September 30, 2017, Aratana recorded $15.1 mln in net revenues compared to $38.3 mln in the first nine months of 2016, which primarily resulted from the licensing and collaboration revenues under the collaboration agreement with Elanco. 

LEAWOOD, Kan. (AP) _ Aratana Therapeutics Inc. (PETX) on Thursday reported a loss of $8.9 million in its third quarter.

On a per-share basis, the Leawood, Kansas-based company said it had a loss of 21 cents.

The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 26 cents per share.

The developer of pet medications posted revenue of $6.2 million in the period.

Aratana shares have fallen 24 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $5.46, a drop of 31 percent in the last 12 months.